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ABSTRACT
Background: Flavonoid-rich foods have antiinflammatory, an-
tiatherogenic, and antithrombotic properties that may contribute to
a lower risk of ischemic stroke.
Objectives: We aimed to investigate the relationship between
habitual flavonoid consumption and incidence of ischemic stroke in
participants from the Danish Diet, Cancer and Health Study.
Design: In this prospective cohort study, 55,169 Danish residents
without a prior ischemic stroke [median (IQR) age at enrolment
of 56 y (52–60)], were followed for 21 y (20–22). We used
Phenol-Explorer to estimate flavonoid intake from food frequency
questionnaires obtained at study entry. Incident cases of ischemic
stroke were identified from Danish nationwide registries and
restricted cubic splines in Cox proportional hazards models were
used to investigate relationships with flavonoid intake.
Results: During follow-up, 4237 individuals experienced an is-
chemic stroke. Compared with participants in Q1 and after
multivariable adjustment for demographics and lifestyle factors,
those in Q5—for intake of total flavonoids, flavonols, and flavanol
oligo + polymers—had a 12% [HR (95% CI): 0.88 (0.81, 0.96)],
10% [0.90 (0.82, 0.98)], and 18% [0.82 (0.75, 0.89)] lower risk of
ischemic stroke incidence, respectively. Multivariable (demographic
and lifestyle) adjusted associations for anthocyanins and flavones
with risk of ischemic stroke were not linear, with moderate but
not higher intakes associated with lower risk [anthocyanins Q3
vs. Q1 HR (95% CI): 0.85 (0.79, 0.93); flavones: 0.90 (0.84,
0.97)]. Following additional adjustment for dietary confounders,
similar point estimates were observed; however, significance was
only retained for anthocyanins and flavanol oligo + polymers
[anthocyanins Q3 vs. Q1 HR (95% CI): 0.86 (0.79, 0.94); flavanol
oligo + polymers Q5 vs. Q1 0.86 (0.78, 0.94)].
Conclusions: These findings suggest that moderate habitual con-
sumption of healthy flavonoid-rich foods is associated with a
lower risk of ischemic stroke and further investigation is therefore
warranted. Am J Clin Nutr 2021;00:1–10.
Keywords: nutrition, flavonoids, ischemic stroke, epidemiology,
prospective cohort
Introduction
Globally, stroke is a major cause of disability and mortality
whose socioeconomic burden continues to rise with the increas-
ing aging population (1). Total stroke, including both ischemic
and hemorrhagic, is the second leading cause of death worldwide
(2). Approximately 80% of all stroke cases, including fatal
and nonfatal, are ischemic, although this varies by population
(2). Vessel occlusion, occurring in ischemic stroke, is mostly
a consequence of atherosclerosis and cardioembolisms, while
hemorrhagic stroke, due to vessel rupture, is caused by different
underlying pathogenic mechanisms typically involving hyperten-
sion and cerebral amyloid deposition (3–5). Flavonoids, present
in foods such as tea, cocoa, nuts, fruits, and vegetables, have
shown antiinflammatory, antiatherogenic, and antithrombotic
properties and are suggested to play a role in protecting against
ischemic stroke (6). We have previously shown that higher intakes
of total flavonoids are associated with lower atherosclerotic
cardiovascular disease hospitalizations, including lower ischemic
stroke hospitalizations (7). However, further to this, only a limited
number of other studies have investigated associations between
intakes of flavonoids and ischemic stroke risk (8–11). Generally,
Am J Clin Nutr 2021;00:1–10. Printed in USA. © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
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these studies provide support that higher intakes of the flavonol,
flavanone, and anthocyanin subclasses are associated with a lower
risk of ischemic stroke, although results have been mixed (8–11).
We have also previously observed that subpopulations prone to
atherosclerosis, such as smokers and high alcohol consumers,
might stand to benefit the most from higher flavonoid intakes
(7, 12); whether these results are consistent with outcomes for
ischemic stroke requires investigation. The present study was
therefore performed to 1) investigate the association between
intakes of total flavonoids, flavonoid subclasses, and major
flavonoid compounds with ischemic stroke incidence, and 2)




The Danish Diet, Cancer and Health Study is a prospective
cohort investigation of nutrition, cancer, and other chronic
diseases, described in detail previously (13). The study was
approved by the Danish Data Protection Agency (Ref no 2012–
58–0004 I-Suite nr: 6357, VD-2018–117) and all participants
provided informed consent. Requests to access the dataset may
be sent to the Diet, Cancer and Health Steering Committee at
the Danish Cancer Society. Briefly, between 1993 and 1997,
160,725 men and women, aged 50–64 y, who lived in the
Copenhagen and Aarhus areas of Denmark, were invited to
participate. Invitation was accepted by 57,053 people and the
participants attended study centers for baseline assessment.
Participants completed a self-administered, interviewer-checked
questionnaire on sociodemographic factors and health behavior,
while anthropometric measures and blood samples were obtained
by professional staff. Dietary intake was assessed by a 192-
item FFQ. Participants were then followed prospectively using
Danish nationwide registries to identity and record follow-up
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information. Key registries included the Civil Registration Sys-
tem, which provides information on vital status and emigration;
the Integrated Database for Labor Market Research, which
contains annual income data; the Danish Registry of Causes of
Death, which provides information on mortality; and the Danish
National Patient Register (DNPR), which has recorded nearly
all (∼99.4%) hospital admissions in Denmark since 1978. The
DNPR further includes diagnosis information, classified until
1993 according to the International Classification of Diseases
(ICD), 8th Revision (ICD-8) and thereafter, according to the
10th Revision (ICD-10) (14). A total of 56,267 participants
completed a FFQ with plausible energy intakes (500 to 5000
kcal/d) and were without a cancer diagnosis prior to enrolment.
After excluding participants with a history of ischemic stroke
at baseline (n = 887) and missing or extreme covariate outliers
(n = 211), 55,169 participants remained for analysis. The study
flow diagram is shown in Supplementary Figure 1.
Assessment of diet and flavonoid intake
Calculations of nutrient and flavonoid intake have been
described previously (7, 13, 15). Briefly, data on the flavonoid
content of foods were obtained from Phenol-Explorer (without
hydrolysis of glycosides or esters) and the effect of food
processing was taken into consideration using retention factors
(16). Intakes of individual flavonoid compounds were estimated
using the flavonoid content reported in Phenol-Explorer for
each food and beverage item in the FFQ. Based on chemical
structure, all individual flavonoid compounds were summed
into subclasses including: flavonols, flavanol monomers, flavanol
oligo + polymers (including theaflavins), flavanones, flavones,
anthocyanins, isoflavones, dihydrochalcones, dihydroflavonols,
and chalcones. Total flavonoid intake was calculated as the
sum of all individual flavonoid compounds from all food
sources. Following these calculations, exposures were intakes of
total flavonoids, flavonoid subclasses, and individual flavonoid
compounds with mean intakes of >5mg/d. In our prior work,
we report a supplementary table showing the individual flavonoid
compounds included in each subclass and total flavonoid intake
(15).
Study outcomes
The primary outcome was death from, or first-time hospitaliza-
tion for, ischemic stroke. Stroke hospitalizations were identified
through primary or secondary diagnosis codes for ischemic stroke
(ICD-10: I63 and I64) in the DNPR. The ICD codes for stroke
hospitalization have a positive predictive value between 80.5%
and 85% in the DNPR (17, 18). Stroke-related mortality was
defined as an ICD-10 diagnosis registered as a cause of death
related to ischemic stroke (ICD-10: I63 and I64).
Validated case analysis
To verify the registry-based outcomes, we re-examined
associations using only medically reviewed and validated cases of
first-time ischemic stroke (ICD-10: I63), with follow-up between
March 1994 and November 2009. The methods for validating
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Covariates
Data on sex, age, education, smoking habits, alcohol con-
sumption, daily activity, anthropometry, cholesterol, medication
use, and diet were obtained from the baseline assessment. As
an indicator of socioeconomic status, each participant’s average
annual income over 5 y (defined as household income after
taxation and interest, for the value of the Danish currency in 2015)
was used. For hypertension and diabetes mellitus, self-reported
data were used due to the underreporting of these diagnoses in the
DNPR (19). Self-reported myocardial infarction at baseline was
combined with ICD codes (Supplementary Table 1) of ischemic
heart disease dated prior to participant enrolment. ICD codes
dated prior to participant enrolment were used to identify baseline
comorbidities of peripheral artery disease, hemorrhagic stroke,
chronic kidney disease, chronic obstructive pulmonary disease,
heart failure, and atrial fibrillation (Supplementary Table 1).
Statistical analysis
Time-to-event was defined as the time from date of enrolment
to the date of an ischemic stroke event, death, emigration (loss to
follow-up), or end of follow-up (August 2017), whichever came
first. Nelson-Aalen plots of cumulative incidence for stroke with a
competing risk of death were computed. In our primary analyses,
restricted cubic splines in Cox proportional hazards models were
used to investigate nonlinear relationships between flavonoid
intakes and ischemic stroke outcomes. Proportional hazards as-
sumptions were tested by visually inspecting log–log plots of the
survival function versus time, with no violation found. All HRs
and 95% CIs were obtained from the model with the exposure
fitted as a continuous variable; HR estimates are reported for the
median intake in each quintile with the first quintile median as
the reference point. For these analyses, all deaths were censored
rather than treated as a competing risk (20). Three models of
adjustment were used: 1) minimally adjusted: age (y) and sex
(male/female); 2) multivariable-adjusted: age, sex, BMI (kg/m2),
smoking status (current/former/never), physical activity (total
daily metabolic equivalent), pure alcohol intake (g/d), education
(≤7/8–10/≥11 y), and social economic status (income); 3)
multivariable-adjusted including potential dietary confounders;
covariates in Model 2 plus intakes (g/d) of fish, red meat,
processed meat, polyunsaturated fatty acids, monounsaturated
fatty acids, saturated fatty acids, and energy (kJ/d). Covariates
were chosen a priori to the best of our knowledge of potential
confounders of flavonoid intake and stroke. We also conducted
exploratory analysis to test the robustness of our results. In
addition to covariates in Models 2 and 3 we added separately
into the models, a history of hypertension, hypercholesterolemia,
diabetes, ischemic heart disease, peripheral artery disease,
atrial fibrillation, chronic obstructive pulmonary disease, and
chronic kidney disease, which may act as confounders and/or
intermediates on the causal pathway linking flavonoid intake
with ischemic stroke risk. In secondary analyses, we investigated
whether associations differed in the presence of ischemic stroke
risk factors, by stratifying by known risk factors for stroke (21).
We excluded all participants with an alcohol intake of zero
(n = 1261) and a BMI < 18.5 (n = 440) when stratifying by
alcohol intake and BMI, respectively, due to potential underlying
pathologies or habits that may increase cardiovascular disease
(CVD) risk. When stratifying by smoking status (never/ever),
alcohol intake, and BMI, the corresponding continuous variables
(smoking pack-years, alcohol intake, and BMI, respectively)
were included in the model where appropriate to account
for residual confounding. We tested for interactions using a
chi-squared test comparing nested models. Standard logistic
regression models were used to obtain the 20-y absolute risk
estimates of incident ischemic stroke. Unless indicated by the
stratification variable, these estimates are for the “average” cohort
participant at baseline, i.e., a nonsmoking participant, aged 56
y, with a BMI of 25.5 kg/m2, a total daily metabolic equivalent
score of 56, with a mean household income of 394,701–570,930
DKK/y, and an alcohol intake of 13 g/d, presented separately for
males and females. All analyses were undertaken using Stata/IC
14.2 (StataCorp LLC) and R statistics (R Core Team, 2019)
(22). Statistical significance was set at P ≤ 0.05 (2-tailed) for all
tests.
Results
During a median (IQR) follow-up of 21 y (20–22), 4237
incident cases (both fatal and nonfatal) of ischemic stroke
occurred. A total of 11,808 participants died without having an
ischemic stroke. The cumulative incidence of ischemic stroke and
death without a prior ischemic stroke is shown in Supplementary
Figure 2. Participants had a median (IQR) age at enrolment of
56 y (52–60) and a total flavonoid intake of 496 mg/d (287–
805) (Table 1). Compared with participants with the lowest
flavonoid intakes, those with the highest intakes were more likely
to be female, have a lower BMI, be more physically active,
have a higher education and income, and were less likely to
have ever smoked; they also tended to eat more fish, fiber,
fruits, and vegetables, and eat less red and processed meat
(Table 1).
Associations between total habitual flavonoid intake and
ischemic stroke incidence
Total flavonoid intake was associated with lower ischemic
stroke incidence after multivariable adjustment for demographics
and lifestyle factors (Model 2, Table 2). Restricted cubic splines
showed a nonlinear inverse association; the association plateaued
at intakes of ∼500 mg/d (Figure 1, Table 2). Compared with
those with the lowest total flavonoid intakes (Q1), participants
with the highest intakes (Q5) had a 12% lower risk of ischemic
stroke [HR: 0.88 (95% CI: 0.81, 0.96)] after multivariable
adjustment. After further adjustment for dietary confounders,
the association was no longer significant (Model 3, Table 2).
Using only validated first-time cases, 977 participants were
hospitalized for an ischemic stroke. Compared with participants
in Q1, those in Q5 had a 17% lower risk of ischemic stroke
[Model 2 HR: 0.83 (95% CI: 0.69, 0.99); Supplementary Figure
3]. In exploratory analysis, the addition of intermediate and/or
confounding conditions to Models 2 and 3, including history
of hypertension, hypercholesterolemia, diabetes, ischemic heart
disease, peripheral artery disease, atrial fibrillation, chronic
obstructive pulmonary disease, and chronic kidney disease,
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Associations between habitual flavonoid subclass intakes
and ischemic stroke incidence
Intakes of flavonols and flavanol oligo + polymers were
inversely associated with incidence of ischemic stroke (Figure 2)
with the lowest relative risks observed for those in Q5 [flavonols
Q5 vs. Q1 HR (95% CI): 0.90 (0.82, 0.98); flavanol oligo + poly-
mers Q5 vs. Q1 HR (95% CI): 0.82 (0.75, 0.89); Model
2; Table 2]. The association remained statistically significant
for intakes of flavanol oligo + polymer, but not flavonols,
following additional adjustment for dietary confounders (Model
3; Table 2). Associations for anthocyanins and flavones were U-
shaped (Figure 2); the lowest relative risks of ischemic stroke
were observed for moderate consumers [anthocyanins Q3 vs.
Q1 HR (95% CI): 0.85 (0.79, 0.93); flavones Q3 vs. Q1 HR
(95% CI): 0.90 (0.84, 0.97); Model 2; Table 2]. The association
remained statistically significant for intakes of anthocyanins,
but not flavones, following additional adjustment for dietary
confounders (Model 3; Table 2). Intakes of flavanones and
flavanol monomers were not associated with ischemic stroke
(Figure 2 and Table 2). In exploratory analysis, further adjustment
for intermediate and/or confounding conditions did not materially
change the results of Models 2 or 3 for all subclasses, except for
flavones, where further adjustment attenuated the relationship in
Model 2 (Models 4 and 5, Supplementary Table 2).
Associations between habitual major flavonoid compound
intakes and ischemic stroke incidence
Of the flavonol compounds investigated, quercetin but not
kaempferol, was nonlinearly associated with lower ischemic
stroke risk; the inverse association plateaued at moderate intakes
[quercetin Q3 vs. Q1 HR (95% CI): 0.92 (0.85, 0.99); Model 2;
Figure 3; Supplementary Table 3]. Following additional adjust-
ment for dietary confounders, neither quercetin nor kaempferol
were significantly associated with ischemic stroke risk (Model 3;
Supplementary Table 3). Both flavanol oligomers examined, that
is, proanthocyanidin dimers and proanthocyanidin trimers, were
nonlinearly associated with lower ischemic stroke risk, as was the
flavanol monomer epicatechin; the significant inverse association
plateaued for all at moderate intakes [proanthocyanidin dimers
Q2 vs. Q1 HR (95% CI): 0.94 (0.88, 0.99); proanthocyanidin
trimers Q2 vs. Q1 HR (95% CI): 0.92 (0.87, 0.97); epicatechin
Q2 vs. Q1 HR (95% CI): 0.92 (0.87, 0.98); Model 2; Figure 3;
Supplementary Table 3] and was unchanged in Model 3.
Concerning anthocyanin compounds, higher intakes of malvidin
were associated with lower ischemic stroke risk in all models
[malvidin Q2 vs. Q1 HR (95% CI): 0.93 (0.89, 0.97); Model
2]; however, associations for cyanidin and delphinidin were
U-shaped; a lower risk of ischemic stroke was observed for
moderate consumption [cyanidin Q3 vs. Q1 HR (95% CI): 0.90
(0.84, 0.97); delphinidin Q3 vs. Q1 HR (95% CI): 0.85 (0.78,
0.93) Model 2; Figure 3; Supplementary Table 3]. Following
adjustment for dietary intake, significance was attenuated for
cyanidin but not delphinidin (Model 3; Supplementary Table
3). The flavone apigenin was also associated with ischemic
stroke in a U-shaped pattern [apigenin Q3 vs. Q1 HR (95%
CI): 0.91 (0.85, 0.98); Model 2], although this was attenuated
following adjustment for diet (Model 3; Supplementary Table
3). No association was observed for the flavanone hesperidin
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No. events 1020 873 846 779 719
Intake (mg/d)∗ 174 (6–252) 321 (252–395) 496 (395–602) 727 (602–910) 1201 (910–3552)
HR (95% CI)
Model 1 ref. 0.86 (0.82, 0.92) 0.78 (0.73, 0.84) 0.75 (0.70, 0.81) 0.72 (0.66, 0.78)
Model 2 ref. 0.94 (0.89, 0.99) 0.90 (0.84, 0.97) 0.90 (0.83, 0.97) 0.88 (0.81, 0.96)
Model 3 ref. 0.95 (0.89, 1.01) 0.92 (0.85, 1.00) 0.92 (0.85, 1.00) 0.92 (0.84, 1.01)
Flavonols
No. events 1016 892 841 792 696
Intake (mg/d)∗ 15 (0–21) 26 (21–32) 39 (32–50) 66 (50–83) 116 (83–251)
HR (95% CI)
Model 1 ref. 0.89 (0.84, 0.94) 0.81 (0.76, 0.88) 0.75 (0.70, 0.81) 0.73 (0.67, 0.79)
Model 2 ref. 0.96 (0.91, 1.01) 0.93 (0.86, 1.00) 0.91 (0.84, 0.99) 0.90 (0.82, 0.98)
Model 3 ref. 0.96 (0.91, 1.01) 0.93 (0.86, 1.01) 0.92 (0.85, 1.01) 0.93 (0.84, 1.02)
Flavanol monomers
No. events 1024 844 883 781 705
Intake (mg/d)∗ 14 (0–21) 30 (21–46) 67 (46–115) 261 (115–282) 473 (282–916)
HR (95% CI)
Model 1 ref. 0.94 (0.90, 0.97) 0.85 (0.78, 0.92) 0.76 (0.70, 0.83) 0.75 (0.69, 0.82)
Model 2 ref. 0.98 (0.95, 1.02) 0.95 (0.88, 1.04) 0.93 (0.85, 1.01) 0.93 (0.85, 1.01)
Model 3 ref. 0.99 (0.95, 1.03) 0.98 (0.90, 1.06) 0.96 (0.88, 1.04) 0.96 (0.88, 1.04)
Flavanol oligo + polymers
No. events 1010 944 798 768 717
Intake (mg/d)∗ 92 (0–136) 179 (136–217) 256 (217–303) 360 (303–434) 537 (434–2254)
HR (95% CI)
Model 1 ref. 0.84 (0.79, 0.90) 0.76 (0.71, 0.82) 0.71 (0.66, 0.77) 0.68 (0.63, 0.74)
Model 2 ref. 0.93 (0.87, 0.99) 0.88 (0.82, 0.95) 0.84 (0.78, 0.91) 0.82 (0.75, 0.89)
Model 3 ref. 0.94 (0.88, 1.00) 0.89 (0.83, 0.96) 0.86 (0.79, 0.94) 0.86 (0.78, 0.94)
Anthocyanins
No. events 996 761 783 841 856
Intake (mg/d)∗ 5 (0–10) 13 (10–17) 20 (17–24) 36 (24–53) 70 (53–397)
HR (95% CI)
Model 1 ref. 0.81 (0.76, 0.86) 0.74 (0.69, 0.81) 0.78 (0.72, 0.84) 0.86 (0.79, 0.94)
Model 2 ref. 0.89 (0.84, 0.95) 0.85 (0.79, 0.93) 0.87 (0.80, 0.94) 0.92 (0.84, 1.01)
Model 3 ref. 0.90 (0.85, 0.96) 0.86 (0.79, 0.94) 0.88 (0.81, 0.96) 0.94 (0.86, 1.03)
Flavanones
No. events 917 811 859 782 868
Intake (mg/d)∗ 3 (0–6) 9 (6–13) 18 (13–26) 32 (26–49) 70 (49–564)
HR (95% CI)
Model 1 ref. 0.94 (0.89, 0.99) 0.89 (0.82, 0.97) 0.89 (0.83, 0.96) 0.94 (0.86, 1.01)
Model 2 ref. 0.98 (0.93, 1.04) 0.97 (0.89, 1.06) 0.98 (0.91, 1.06) 1.01 (0.93, 1.10)
Model 3 ref. 0.99 (0.93, 1.04) 0.98 (0.90, 1.07) 0.99 (0.92, 1.07) 1.03 (0.95, 1.12)
Flavones
No. events 919 855 787 811 865
Intake (mg/d)∗ 2 (0–3) 4 (3–4) 5 (4–6) 7 (6–9) 11 (9–51)
HR (95% CI)
Model 1 ref. 0.86 (0.81, 0.91) 0.81 (0.75, 0.87) 0.81 (0.76, 0.87) 0.87 (0.80, 0.94)
Model 2 ref. 0.93 (0.87, 0.98) 0.90 (0.84, 0.97) 0.92 (0.85, 0.99) 0.96 (0.89, 1.04)
Model 3 ref. 0.94 (0.88, 1.00) 0.93 (0.86, 1.00) 0.95 (0.88, 1.03) 1.02 (0.93, 1.12)
1Hazard ratios (95% CI) for first-time ischemic stroke during 21 y of follow-up, obtained from restricted cubic splines in Cox proportional hazards
models. Model 1 adjusted for age and sex; Model 2 adjusted for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and social
economic status (income); Model 3 adjusted for all covariates in Model 2 plus intakes of fish, red meat, processed meat, polyunsaturated fatty acids,
monounsaturated fatty acids, saturated fatty acids, and energy.
∗Median; range in parentheses (all such values). Intake quintiles are mutually exclusive.
Associations between habitual total flavonoid intake and
ischemic stroke incidence stratified by risk factors for stroke
The association between total flavonoid intake and ischemic
stroke was present in all subgroups investigated (Pinteraction ≥ 0.05
for all); the shape of the associations appeared similar to that
seen in the whole population except in those with a BMI of
>30 kg/m2 for which the association appeared more U-shaped
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FIGURE 1 Cubic spline curves describing the association between total
flavonoid intake and total (first-time) ischemic stroke events (n = 4237)
among participants of the Danish Diet, Cancer and Health cohort. Hazard
ratios are based on Cox proportional hazards models adjusted for age, sex,
BMI, smoking status, physical activity, alcohol intake, education, and social
economic status (income) and are comparing the specific level of flavonoid
intake (horizontal axis) to the median intake for participants in the lowest
intake quintile (174 mg/d).
in the estimated risk of an ischemic stroke [risk for a person
with a high flavonoid intake (Q5) – risk for a person with a low
flavonoid intake (Q1)] tended to be higher in smokers (1.22%
males, 0.90% females) than nonsmokers (0.87% males, 0.63%
females), obese participants (1.22% males, 0.88% females)
than non-obese participants (1.19% males, 0.66% females),
and higher alcohol consumers (0.92% males, 0.66% females)
than low alcohol consumers (0.84% males, 0.60% females;
Supplementary Tables 4–6). Moreover, on the absolute scale,
the risk difference across all stratification variables (i.e., smoking
status, alcohol intake, and BMI) was slightly higher in males than
females.
Discussion
Overall, we found a moderate habitual intake of certain
flavonoids are significantly associated with a lower risk of
ischemic stroke. In demographic and lifestyle-adjusted models,
higher intakes of total flavonoids, flavanol oligo + polymers,
and flavonols were significantly associated with lower ischemic
stroke risk, whereas anthocyanins and flavones were associated
in a U-pattern. Following additional adjustment for dietary
confounders, similar point estimates were observed; however,
significance was only retained for anthocyanins and flavanol
oligo + polymers. For major flavonoid compounds, associations
with ischemic stroke risk were also present in demographic
and lifestyle-adjusted models (proanthocyanidin dimers, proan-
thocyanidin trimers, epicatechin, quercetin, apigenin, cyanidin,
delphinidin, and malvidin); these tended to follow the same
pattern as the subclass to which the compound belongs. With
additional adjustment for dietary covariates, significance was
limited to specific anthocyanin and flavanol oligo + polymer
compounds (proanthocyanidin dimers, proanthocyanidin trimers,
and malvidin) in addition to the flavanol monomer epicatechin. In
our effort to identify population subgroups that may benefit the
most from higher flavonoid intakes, we did not find clear evidence
of effect modification by smoking status, BMI, or alcohol intake
on the relative scale.
Prior studies reported conflicting evidence that higher intakes
of flavonols and flavanones might be associated with a lower
risk of ischemic stroke, while for other flavonoid exposures (i.e.,
quercetin, flavones, and total flavonoid) no clear associations
have been observed (8–11, 23). Our study did not find clear
evidence for the involvement of flavanones, yet we did find some
evidence suggesting a possible benefit of quercetin, flavonols,
flavones, and total flavonoid intake on ischemic stroke risk,
although these associations may be due, in part, to differences in
dietary patterns. Prior studies also report conflicting null and ben-
eficial results regarding anthocyanin intake and ischemic stroke
risk; however, those investigating flavanol oligo + polymers have
consistently observed no relationship (8–11). We found both
anthocyanin and flavanol oligo + polymer intake, in addition to
several of their compounds, are associated with lower ischemic
stroke risk independent of established dietary and non-dietary
CVD risk factors. In addition, we found evidence of an inverse
association between epicatechin intake and ischemic stroke risk
independent of diet and lifestyle; however, we did not observe a
role of total monomer intake, which is in agreement with findings
from another cohort (8).
The reasons for apparent inconsistencies in results between
studies on flavonoid intake and ischemic stroke risk are not clear.
Whether the differences in outcomes between studies is due to
differences in the absolute intakes between cohorts, the inclusion
or exclusion of flavonoid-rich foods in FFQs, differences in
other cohort characteristics, chance findings, or combinations of
such limitations is less certain (24). One hypothesis is that the
associations observed may represent a signal of the flavonoids
acting in concert with the co-occurring nutrient matrix within
flavonoid-rich foods, rather than a benefit of the compounds
per se (24, 25). If this is true, then differences in the patterns
of the flavonoid food sources consumed may account for the
different outcomes of the prospective cohort studies described.
It may also explain the U-shaped associations observed for the
anthocyanin and flavone subclasses; that is, significance in the
highest exposure category might have been attenuated due to
introduced confounding, as higher intakes of certain co-occurring
components in flavonoid-bearing foods or mixed meals may exert
detrimental actions (e.g., anthocyanin-rich juice may provide
excess sugar intake or processed flours reported to contain higher
flavones may be otherwise nutrient-poor). Interestingly, although
the anthocyanin subclass was associated with ischemic stroke
incidence in a U-shaped pattern, the anthocyanin compound
malvidin was associated with a lower risk of ischemic stroke
across Q2 to Q5 in comparison with Q1. In this cohort, the
primary dietary source of malvidin was red wine, pointing to a
potential protective association between red wine consumption
and ischemic stroke.
The pathology of ischemic stroke is complex. Randomized
controlled trials (RCTs) of flavonoids and flavonoid-rich foods
have shown that they exert several antiatherogenic actions
including the capacity to beneficially modulate blood pressure,
endothelial function, and arterial stiffness (24). At the same
time, flavonoids have demonstrated antithrombotic and antiin-
flammatory properties (26, 27). Collectively, these actions may
facilitate a lower risk of ischemic stroke. However, up to ∼25%
of all ischemic strokes can be cryptogenic in nature, while up to
∼5% can be due to other rarer causes (e.g., infectious disease)
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FIGURE 2 Hazard ratios based on cubic spline curves to describe the association between flavonoid subclass intakes (mg/d) and total (first-time) ischemic
stroke events (n = 4237) among participants of the Danish Diet, Cancer and Health cohort. Hazard ratios are based on Cox proportional hazards models adjusted
for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and social economic status (income) and are comparing the specific level of
flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile.
stroke but not others, then differences in the causes of ischemic
stroke comprising the outcome events between cohort studies
or even between quantiles within cohorts could potentially lead
to different findings. For example, a well-known risk factor
for stroke, atrial fibrillation, was not associated with flavonoid
intake (28). However, we found that peripheral vascular disease
was highly associated with flavonoid intake (7, 12), which
could indicate the primary mechanism of flavonoids in reducing
ischemic stroke is to reduce overall atherogenesis. For these
reasons, further investigation focusing on flavonoid intake and
ischemic stroke subtypes would be of value.
In our study, on the relative scale, associations did not differ
for subgroups at a higher risk of atherosclerosis. However,
on the absolute scale, subpopulations with risk factors for
atherosclerosis (including smokers, high alcohol consumers,
males, and obese participants) had a modest, yet larger, absolute
risk difference than their counterparts. In line with our prior
research, this might indicate that subpopulations prone to
atherosclerosis may benefit the most from higher flavonoid
intakes, although further investigation is needed to support these
preliminary enquiries (7, 12).
The limitations of the present study include possible mea-
surement error relating to the use of self-report subjective
measures such as diet, physical activity, etc. While the FFQ
used ascertained the frequency of strawberry consumption, it
did not capture intakes of other berries, a major food source of
anthocyanins. The use of an observational design also restricts
our ability to infer causality or to exclude the possibility of
confounding by unmeasured or residual factors. Additionally,
dietary data and covariate information were obtained at baseline
and it is unclear how these might have changed over time.
However, any misclassification error arising would have likely
attenuated any observed associations. Despite this, the lower
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FIGURE 3 Hazard ratios based on cubic spline curves to describe the association between major flavonoid compound intakes and total (first-time) ischemic
stroke events (n = 4237) among participants of the Danish Diet, Cancer and Health cohort. Hazard ratios are based on Cox proportional hazards models adjusted
for age, sex, BMI, smoking status, physical activity, alcohol intake, education, and social economic status (income) and are comparing the specific level of
flavonoid compound intake (horizontal axis) to the median intake for participants in the lowest intake quintile.
major indicators of a healthy lifestyle suggesting that higher
intake of certain flavonoid-rich foods may be associated with
a lower risk of ischemic stroke. However, because the Danish
population is more homogeneous than many other countries, the
generalizability of our results is limited.
Conclusions
In conclusion, moderate habitual intakes of certain flavonoid
subclasses and compounds appear to be associated with a lower
risk of ischemic stroke. Further prospective studies are needed
to confirm these observations as well as RCTs to disentangle
the relative influence of flavonoid compounds on markers of
stroke risk. Nonetheless, these findings provide support for the
consumption of healthy flavonoid-rich foods and highlight the
potential to improve population health in future health-promotion
policies, practices, or programs targeting nutrition.
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